South AfricaTuberculosis profile
Population  2014 54 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 24 (22–26) 44 (41–48)
Mortality (HIV+TB only) 72 (58–89) 134 (107–164)
Prevalence  (includes HIV+TB) 380 (210–590) 696 (390–1 088)
Incidence  (includes HIV+TB) 450 (400–510) 834 (737–936)
Incidence (HIV+TB only) 270 (240–310) 509 (439–584)
         
Case detection, all forms (%) 68 (61–77)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.8 (1.4–2.3) 6.7 (5.4–8.2)
MDR-TB cases among notified pulmonary
TB cases
4 700 (3 700–5 900) 1 500 (1 200–1 800)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 155 473   7 430
Pulmonary, clinically diagnosed 106 482   2 693
Extrapulmonary 33 522   566
       
Total new and relapse 306 166    
Previously treated, excluding relapses 12 027    
Total cases notified 318 193    
Among 306 166 new and relapse cases:
31 977 (10%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB     218 231
Laboratory-confirmed RR-/MDR-TB cases     18 734
Patients started on MDR-TB treatment ***     11 538
TB/HIV 2014 Number (%)
TB patients with known HIV status 295 136 (93)
HIV-positive TB patients 179 756 (61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 155 017 (86)
HIV-positive TB patients on antiretroviral therapy (ART) 141 755 (79)
HIV-positive people screened for TB 1 148 477  
HIV-positive people provided with IPT 551 787  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (78) 321 087
Previously treated cases, excluding relapse, registered in 2013 (69) 18 292
HIV-positive TB cases, all types, registered in 2013 (76) 191 189
RR-/MDR-TB cases started on second-line treatment in 2012 (49) 8 084
XDR-TB cases started on second-line treatment in 2012 (20) 607
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 207
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 248
% Funded domestically 84%
% Funded internationally 8%
% Unfunded 8%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-28 Data: www.who.int/tb/data